Your browser doesn't support javascript.
loading
Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers.
Atallah, Ghofraan Abdulsalam; Kampan, Nirmala Chandralega; Chew, Kah Teik; Mohd Mokhtar, Norfilza; Md Zin, Reena Rahayu; Shafiee, Mohamad Nasir Bin; Abd Aziz, Nor Haslinda Binti.
Afiliación
  • Atallah GA; Department of Obstetrics and Gynaecology, Faculty of Medicine, University Kebangsaan Malaysia, Bandar Tun Razak 56000, Kuala Lumpur, Malaysia.
  • Kampan NC; Department of Obstetrics and Gynaecology, Faculty of Medicine, University Kebangsaan Malaysia, Bandar Tun Razak 56000, Kuala Lumpur, Malaysia.
  • Chew KT; Department of Obstetrics and Gynaecology, Faculty of Medicine, University Kebangsaan Malaysia, Bandar Tun Razak 56000, Kuala Lumpur, Malaysia.
  • Mohd Mokhtar N; Department of Physiology, Faculty of Medicine, University Kebangsaan Malaysia, Bandar Tun Razak 56000, Kuala Lumpur, Malaysia.
  • Md Zin RR; Department of Pathology, Faculty of Medicine, University Kebangsaan Malaysia, Bandar Tun Razak 56000, Kuala Lumpur, Malaysia.
  • Shafiee MNB; Department of Obstetrics and Gynaecology, Faculty of Medicine, University Kebangsaan Malaysia, Bandar Tun Razak 56000, Kuala Lumpur, Malaysia.
  • Abd Aziz NHB; Department of Obstetrics and Gynaecology, Faculty of Medicine, University Kebangsaan Malaysia, Bandar Tun Razak 56000, Kuala Lumpur, Malaysia.
Int J Mol Sci ; 24(3)2023 Jan 19.
Article en En | MEDLINE | ID: mdl-36768291
Ovarian cancer is a lethal reproductive tumour affecting women worldwide. The advancement in presentation and occurrence of chemoresistance are the key factors for poor survival among ovarian cancer women. Surgical debulking was the mainstay of systemic treatment for ovarian cancer, which was followed by a successful start to platinum-based chemotherapy. However, most women develop platinum resistance and relapse within six months of receiving first-line treatment. Thus, there is a great need to identify biomarkers to predict platinum resistance before enrolment into chemotherapy, which would facilitate individualized targeted therapy for these subgroups of patients to ensure better survival and an improved quality of life and overall outcome. Harnessing the immune response through immunotherapy approaches has changed the treatment way for patients with cancer. The immune outline has emerged as a beneficial tool for recognizing predictive and prognostic biomarkers clinically. Studying the tumour microenvironment (TME) of ovarian cancer tissue may provide awareness of actionable targets for enhancing chemotherapy outcomes and quality of life. This review analyses the relevance of immunohistochemistry biomarkers as prognostic biomarkers in predicting chemotherapy resistance and improving the quality of life in ovarian cancer.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas Tipo de estudio: Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Female / Humans Idioma: En Revista: Int J Mol Sci Año: 2023 Tipo del documento: Article País de afiliación: Malasia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas Tipo de estudio: Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Female / Humans Idioma: En Revista: Int J Mol Sci Año: 2023 Tipo del documento: Article País de afiliación: Malasia Pais de publicación: Suiza